白细胞介素-2 受体(IL-2R)激动剂在肿瘤免疫治疗中的现状与未来前景
Current landscape and future prospects of interleukin-2 receptor (IL-2R) agonists in cancer immunotherapy.
然而,不到50%的患者从ICB中获益,这凸显了对更有效免疫治疗选择的需求。
50.3分
★★★☆☆
FRONTIER PAPERS
Current landscape and future prospects of interleukin-2 receptor (IL-2R) agonists in cancer immunotherapy.
然而,不到50%的患者从ICB中获益,这凸显了对更有效免疫治疗选择的需求。
Generation and Characterization of Ex Vivo Expanded Tumor-infiltrating Lymphocytes From Renal Cell Carcinoma Tumors for Adoptive Cell Therapy.
自体治疗性TIL(肿瘤浸润淋巴细胞)疗法是一种增强抗肿瘤免疫的有前景的策略。
共 2 条
MEMBER ACCOUNT
登录成功会直接打开下一页。